Cargando…

术后放疗在期Ⅰ/Ⅱ期/Ⅲ期胸腺肿瘤中的作用——ChART回顾性数据库研究结果

BACKGROUND AND OBJECTIVE: Postoperative radiotherapy (PORT) for thymic tumor is still controversial. The object of the study is to evaluate the role of PORT for stage Ⅰ/Ⅱ/Ⅲ thymic tumor. METHODS: The database of Chinese Alliance of Research for Thymomas (ChART) was retrieved for patients with stage...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6133973/
https://www.ncbi.nlm.nih.gov/pubmed/27339724
http://dx.doi.org/10.3779/j.issn.1009-3419.2016.07.09
_version_ 1783354583068704768
collection PubMed
description BACKGROUND AND OBJECTIVE: Postoperative radiotherapy (PORT) for thymic tumor is still controversial. The object of the study is to evaluate the role of PORT for stage Ⅰ/Ⅱ/Ⅲ thymic tumor. METHODS: The database of Chinese Alliance of Research for Thymomas (ChART) was retrieved for patients with stage Ⅰ/Ⅱ/Ⅲ thymic tumor who underwent surgical therapy without neoajuvant therapy between 1994 and 2012. Univariate and multivariate survival analyses were performed. Cox proportional hazard model was used to determine the hazard ratio for death. RESULTS: 1, 546 stage Ⅰ/Ⅱ/Ⅲ patients were identifed from ChART database. Among these patients, 649 (41.98%) underwent PORT. PORT was associated with gender, histologic type (World Health Organization, WHO), surgical extent, complete resection, Masaoka stage and adjuvant chemotherapy. The 5-yr and 10-yr overall survival (OS) rates and disease-free survival (DFS) rate for patients underwent surgery followed by PORT were 90% and 80%, 81% and 63%, comparing with 96% and 95%, 92% and 90% for patients underwent surgery alone (P=0.001, P < 0.001) respectively. In univariate analysis, age, histologic type (WHO), Masaoka stage, completeness of resection, and PORT were associated with OS. Multivariable analysis showed that histologic type (WHO)(P=0.001), Masaoka stage (P=0.029) and completeness of resection (P=0.003) were independently prognostic factors of OS. In univariate analysis, gender, myasthenia gravis, histologic type (WHO), Masaoka stage, surgical approach, PORT and completeness of resection were associated with DFS. Multivariable analysis showed that histologic type (WHO) (P < 0.001), Masaoka stage (P=0.005) and completeness of resection (P=0.006) were independently prognostic factors of DFS. Subgroup analysis showed that patients with incomplete resection underwent PORT achieved the beter OS and DFS (P=0.010, 0.017, respectively). However, patients with complete resection underwent PORT had the worse OS and DFS (P < 0.001, P < 0.001, respectively). CONCLUSION: The current retrospective study indicated that PORT afer incomplete resection could improve OS and DFS for patients with stage Ⅰ/Ⅱ/Ⅲ thymic tumor. But for those afer complete resection, PORT may not help improve prognosis on the whole.
format Online
Article
Text
id pubmed-6133973
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher 中国肺癌杂志编辑部
record_format MEDLINE/PubMed
spelling pubmed-61339732018-10-02 术后放疗在期Ⅰ/Ⅱ期/Ⅲ期胸腺肿瘤中的作用——ChART回顾性数据库研究结果 Zhongguo Fei Ai Za Zhi 2016胸外医师年会特约专题:胸腺肿瘤 BACKGROUND AND OBJECTIVE: Postoperative radiotherapy (PORT) for thymic tumor is still controversial. The object of the study is to evaluate the role of PORT for stage Ⅰ/Ⅱ/Ⅲ thymic tumor. METHODS: The database of Chinese Alliance of Research for Thymomas (ChART) was retrieved for patients with stage Ⅰ/Ⅱ/Ⅲ thymic tumor who underwent surgical therapy without neoajuvant therapy between 1994 and 2012. Univariate and multivariate survival analyses were performed. Cox proportional hazard model was used to determine the hazard ratio for death. RESULTS: 1, 546 stage Ⅰ/Ⅱ/Ⅲ patients were identifed from ChART database. Among these patients, 649 (41.98%) underwent PORT. PORT was associated with gender, histologic type (World Health Organization, WHO), surgical extent, complete resection, Masaoka stage and adjuvant chemotherapy. The 5-yr and 10-yr overall survival (OS) rates and disease-free survival (DFS) rate for patients underwent surgery followed by PORT were 90% and 80%, 81% and 63%, comparing with 96% and 95%, 92% and 90% for patients underwent surgery alone (P=0.001, P < 0.001) respectively. In univariate analysis, age, histologic type (WHO), Masaoka stage, completeness of resection, and PORT were associated with OS. Multivariable analysis showed that histologic type (WHO)(P=0.001), Masaoka stage (P=0.029) and completeness of resection (P=0.003) were independently prognostic factors of OS. In univariate analysis, gender, myasthenia gravis, histologic type (WHO), Masaoka stage, surgical approach, PORT and completeness of resection were associated with DFS. Multivariable analysis showed that histologic type (WHO) (P < 0.001), Masaoka stage (P=0.005) and completeness of resection (P=0.006) were independently prognostic factors of DFS. Subgroup analysis showed that patients with incomplete resection underwent PORT achieved the beter OS and DFS (P=0.010, 0.017, respectively). However, patients with complete resection underwent PORT had the worse OS and DFS (P < 0.001, P < 0.001, respectively). CONCLUSION: The current retrospective study indicated that PORT afer incomplete resection could improve OS and DFS for patients with stage Ⅰ/Ⅱ/Ⅲ thymic tumor. But for those afer complete resection, PORT may not help improve prognosis on the whole. 中国肺癌杂志编辑部 2016-07-20 /pmc/articles/PMC6133973/ /pubmed/27339724 http://dx.doi.org/10.3779/j.issn.1009-3419.2016.07.09 Text en 版权所有©《中国肺癌杂志》编辑部2016 https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/
spellingShingle 2016胸外医师年会特约专题:胸腺肿瘤
术后放疗在期Ⅰ/Ⅱ期/Ⅲ期胸腺肿瘤中的作用——ChART回顾性数据库研究结果
title 术后放疗在期Ⅰ/Ⅱ期/Ⅲ期胸腺肿瘤中的作用——ChART回顾性数据库研究结果
title_full 术后放疗在期Ⅰ/Ⅱ期/Ⅲ期胸腺肿瘤中的作用——ChART回顾性数据库研究结果
title_fullStr 术后放疗在期Ⅰ/Ⅱ期/Ⅲ期胸腺肿瘤中的作用——ChART回顾性数据库研究结果
title_full_unstemmed 术后放疗在期Ⅰ/Ⅱ期/Ⅲ期胸腺肿瘤中的作用——ChART回顾性数据库研究结果
title_short 术后放疗在期Ⅰ/Ⅱ期/Ⅲ期胸腺肿瘤中的作用——ChART回顾性数据库研究结果
title_sort 术后放疗在期ⅰ/ⅱ期/ⅲ期胸腺肿瘤中的作用——chart回顾性数据库研究结果
topic 2016胸外医师年会特约专题:胸腺肿瘤
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6133973/
https://www.ncbi.nlm.nih.gov/pubmed/27339724
http://dx.doi.org/10.3779/j.issn.1009-3419.2016.07.09
work_keys_str_mv AT shùhòufàngliáozàiqīiiiqīiiiqīxiōngxiànzhǒngliúzhōngdezuòyòngcharthuígùxìngshùjùkùyánjiūjiéguǒ
AT shùhòufàngliáozàiqīiiiqīiiiqīxiōngxiànzhǒngliúzhōngdezuòyòngcharthuígùxìngshùjùkùyánjiūjiéguǒ
AT shùhòufàngliáozàiqīiiiqīiiiqīxiōngxiànzhǒngliúzhōngdezuòyòngcharthuígùxìngshùjùkùyánjiūjiéguǒ
AT shùhòufàngliáozàiqīiiiqīiiiqīxiōngxiànzhǒngliúzhōngdezuòyòngcharthuígùxìngshùjùkùyánjiūjiéguǒ
AT shùhòufàngliáozàiqīiiiqīiiiqīxiōngxiànzhǒngliúzhōngdezuòyòngcharthuígùxìngshùjùkùyánjiūjiéguǒ
AT shùhòufàngliáozàiqīiiiqīiiiqīxiōngxiànzhǒngliúzhōngdezuòyòngcharthuígùxìngshùjùkùyánjiūjiéguǒ
AT shùhòufàngliáozàiqīiiiqīiiiqīxiōngxiànzhǒngliúzhōngdezuòyòngcharthuígùxìngshùjùkùyánjiūjiéguǒ
AT shùhòufàngliáozàiqīiiiqīiiiqīxiōngxiànzhǒngliúzhōngdezuòyòngcharthuígùxìngshùjùkùyánjiūjiéguǒ
AT shùhòufàngliáozàiqīiiiqīiiiqīxiōngxiànzhǒngliúzhōngdezuòyòngcharthuígùxìngshùjùkùyánjiūjiéguǒ
AT shùhòufàngliáozàiqīiiiqīiiiqīxiōngxiànzhǒngliúzhōngdezuòyòngcharthuígùxìngshùjùkùyánjiūjiéguǒ
AT shùhòufàngliáozàiqīiiiqīiiiqīxiōngxiànzhǒngliúzhōngdezuòyòngcharthuígùxìngshùjùkùyánjiūjiéguǒ
AT shùhòufàngliáozàiqīiiiqīiiiqīxiōngxiànzhǒngliúzhōngdezuòyòngcharthuígùxìngshùjùkùyánjiūjiéguǒ
AT shùhòufàngliáozàiqīiiiqīiiiqīxiōngxiànzhǒngliúzhōngdezuòyòngcharthuígùxìngshùjùkùyánjiūjiéguǒ
AT shùhòufàngliáozàiqīiiiqīiiiqīxiōngxiànzhǒngliúzhōngdezuòyòngcharthuígùxìngshùjùkùyánjiūjiéguǒ
AT shùhòufàngliáozàiqīiiiqīiiiqīxiōngxiànzhǒngliúzhōngdezuòyòngcharthuígùxìngshùjùkùyánjiūjiéguǒ
AT shùhòufàngliáozàiqīiiiqīiiiqīxiōngxiànzhǒngliúzhōngdezuòyòngcharthuígùxìngshùjùkùyánjiūjiéguǒ
AT shùhòufàngliáozàiqīiiiqīiiiqīxiōngxiànzhǒngliúzhōngdezuòyòngcharthuígùxìngshùjùkùyánjiūjiéguǒ
AT shùhòufàngliáozàiqīiiiqīiiiqīxiōngxiànzhǒngliúzhōngdezuòyòngcharthuígùxìngshùjùkùyánjiūjiéguǒ
AT shùhòufàngliáozàiqīiiiqīiiiqīxiōngxiànzhǒngliúzhōngdezuòyòngcharthuígùxìngshùjùkùyánjiūjiéguǒ
AT shùhòufàngliáozàiqīiiiqīiiiqīxiōngxiànzhǒngliúzhōngdezuòyòngcharthuígùxìngshùjùkùyánjiūjiéguǒ
AT shùhòufàngliáozàiqīiiiqīiiiqīxiōngxiànzhǒngliúzhōngdezuòyòngcharthuígùxìngshùjùkùyánjiūjiéguǒ
AT shùhòufàngliáozàiqīiiiqīiiiqīxiōngxiànzhǒngliúzhōngdezuòyòngcharthuígùxìngshùjùkùyánjiūjiéguǒ
AT shùhòufàngliáozàiqīiiiqīiiiqīxiōngxiànzhǒngliúzhōngdezuòyòngcharthuígùxìngshùjùkùyánjiūjiéguǒ
AT shùhòufàngliáozàiqīiiiqīiiiqīxiōngxiànzhǒngliúzhōngdezuòyòngcharthuígùxìngshùjùkùyánjiūjiéguǒ
AT shùhòufàngliáozàiqīiiiqīiiiqīxiōngxiànzhǒngliúzhōngdezuòyòngcharthuígùxìngshùjùkùyánjiūjiéguǒ